Navigation Links
STALLERGENES: Persistent Efficacy Demonstrated After a Year on Actair(R) Followed by a Second Treatment-Free Year
Date:6/28/2010

rategic markets.

Oralair(R) is the first project resulting from this program. A Mutual Recognition Procedure has been completed in Europe. Having recently demonstrated its efficacy after 3 years of treatment (study VO53.06 conducted in Europe), Oralair(R) has been the subject of a positive phase III trial in adults in the United States (VO61.08).

The second project in the program is Actair(R), dust mite immunotherapy tablet. Following the results of the first year of the phase IIb/III study in allergic rhinitis in adults, a phase III pediatric study has been launched.

The Stalair(R) r Bet v 1 tablet (birch pollen recombinant allergen) has been the subject of a positive phase IIb/III clinical trial conducted in allergic rhinitis caused by birch pollen. A confirmatory phase III study is currently being prepared with a view to EMA registration.

The other allergens concerned by the program are ragweed pollen for the North American market and Japanese cedar pollen for the Japanese market. Altogether, the program covers 80% of the epidemiology for all markets.

ABOUT STALORAL(R) 300

Staloral(R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. It is indicated in the treatment of allergic rhinitis, rhinoconjunctivitis and seasonal or perennial mild to moderate allergic asthma in adults and children over the age of 5 years. Prescribed by allergy specialists, Staloral(R) 300 is particularly aimed at patients suffering from severe allergic diseases inadequately controlled by the use of symptomatic treatments.

In the context of a phase III clinical trial (VO55.06) conducted in

SOURCE Stallergenes
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
2. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
3. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
4. FDA Approves New Device for Adults with Severe and Persistent Asthma
5. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
6. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
7. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
8. New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
9. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
10. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
11. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... , Nov. 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: ... webcasting its corporate presentations at two upcoming investor conferences.  ... London, UK on Tuesday, December 2, 2014 at 6:45 ... vice president and head of EUSA International, will provide an overview ... 26 th Annual Piper Jaffray Healthcare Conference in ...
(Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
... in Management of Transplant Recipients with Cancer, ... in post-transplant patients with cancer is challenging.,Clinicians must ... while,simultaneously monitoring the impact of chemotherapeutic agents on ... management of such patients will be,presented today at ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:11/27/2014)... Most babies and young children don,t need medicines if ... Administration says. Over-the-counter (OTC) cold and cough medicine ... because they could cause serious and potentially deadly side ... three colds a year, but children get them more ... to give them pain relievers, decongestants and other medicines, ...
(Date:11/27/2014)... 27, 2014 The founders of VIM & ... and high functioning compression socks, are proud to announce the ... an innovative Gradient Pressure (TM) knitting technology that is designed ... & VIGR’s commitment to adding flair and style to a ... recently caught the eye of a writer at The ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Two international ... implants procedure will help one person with significant ... Dr. Saj Jivraj and Dr. Mamaly Reshad of the ... Calif., have launched a website devoted to helping dentist ... of the website would be devoted to helping a ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut ... taking FCPX to the next level. , “ProPip allows users ... clicks of a mouse,” said Christina Austin, CEO of Pixel ... will appreciate.” , With ProPip users can show off their ... endless. ProPip is great for commentaries, news casting, and more. ...
(Date:11/27/2014)... 2014 Aria Health President and ... prepared and donated 200 Thanksgiving dinners on Friday, ... , a non-profit, community-based organization committed to serving ... The dinners were assembled in the dining hall ... distributed to vulnerable low income seniors in the ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... Roche Pharmaceuticals has granted a sub-license to Indian firm Hetero ... is the only drug known so far to have any ... virus. ,Hetero is based at Hyderabad and ... distributed across South East Asia and Africa. Commenting on the ...
... gearing up worldover, as the australian health minister ... be provided to all patients visiting queensland// hospital ... smoking following which the Australian Competition and Consumer ... sponsor anti-smoking advertising. ,Cigaretter manufacturers in ...
... and Resorts has banned smoking in the rooms, restaurants, bars ... Canada and the Caribbean from January 2006//., ,Guests will ... outdoor areas. , ,Westin said research among its customers ... room. , ,"Nobody likes to walk into a smoky ...
... has revealed that routine chest X-rays may serve to identify ... 172,000 Americans // are expected to be diagnosed with lung ... as this disease is invariably detected late. ,Earlier ... tumors, or patients were put through risky surgery as a ...
... and Finch showed the effect of childhood infections and ... diseases // . ,They collected mortality data ... and Switzerland from different years but ending with individuals ... was an important factor in treating childhood illness. ...
... Scientists in Scotland have discovered that an ordinary kitchen ... superbug, which is capable of resisting many // antibiotics. ... brand of the kitchen-scouring pad alone contains the cure ... according to reports can be grown on one particular ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: